Royal Bank of Canada’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,164
| Closed | -$46K | – | 7422 |
|
|
2026
Q1 | $46K | Sell |
1,164
-4,408
| -79% | -$113K | ﹤0.01% | 5535 |
|
|
2025
Q4 | $139K | Buy |
5,572
+168
| +3% | +$4.25K | ﹤0.01% | 5008 |
|
|
2025
Q3 | $131K | Sell |
5,404
-2,094
| -28% | -$37.2K | ﹤0.01% | 5347 |
|
|
2025
Q2 | $98K | Buy |
7,498
+743
| +11% | +$9.41K | ﹤0.01% | 5617 |
|
|
2025
Q1 | $97K | Sell |
6,755
-1,588
| -19% | -$26K | ﹤0.01% | 5241 |
|
|
2024
Q4 | $139K | Buy |
8,343
+2,064
| +33% | +$34.2K | ﹤0.01% | 5109 |
|
|
2024
Q3 | $101K | Buy |
6,279
+5,162
| +462% | +$63.2K | ﹤0.01% | 5335 |
|
|
2024
Q2 | $10K | Buy |
1,117
+501
| +81% | +$4.75K | ﹤0.01% | 6327 |
|
|
2024
Q1 | $7K | Buy |
616
+525
| +577% | +$4.97K | ﹤0.01% | 6316 |
|
|
2023
Q4 | $1K | Buy |
91
+71
| +355% | +$476 | ﹤0.01% | 6901 |
|
|
2023
Q3 | $0 | Sell |
20
-165
| -89% | -$1.13K | ﹤0.01% | 7138 |
|
|
2023
Q2 | $1K | Buy |
185
+115
| +164% | +$546 | ﹤0.01% | 6977 |
|
|
2023
Q1 | $0 | Sell |
70
-55
| -44% | -$201 | ﹤0.01% | 7117 |
|
|
2022
Q4 | $0 | Buy |
+125
| New | +$463 | ﹤0.01% | 7281 |
|
|
2021
Q4 | – | Sell |
-453
| Closed | -$8K | – | 7672 |
|
|
2021
Q3 | $8K | Buy |
+453
| New | +$9.38K | ﹤0.01% | 7027 |
|
Royal Bank of Canada's CNTA Position: Q2 2026 in Review
Royal Bank of Canada sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,164 shares — an estimated $46K sold.
Royal Bank of Canada first reported a position in CNTA in Q3 2021 and held it in 15 quarters. The position peaked at $139K in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Royal Bank of Canada reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Royal Bank of Canada sold 1,164 Centessa Pharmaceuticals shares in Q2 2026, an estimated $46K.
- Royal Bank of Canada first reported a position in Centessa Pharmaceuticals in Q3 2021 and held it in 15 quarters.
- Royal Bank of Canada's Centessa Pharmaceuticals position peaked at $139K in Q4 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.